{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:45Z","timestamp":1793239425753,"version":"4.5.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Depression is estimated to be a leading contributor to the global mental health-related burden. The determinants of this huge prevalence lie in the fact that depressive symptoms may be comorbid in a wide variety of disorders, thus complicating and exacerbating their clinical framework. This makes the treatment of depressive symptoms difficult, since many pharmacological interactions should be considered by physicians planning therapy. Hence, depression still represents a challenge for both psychiatrists and other clinicians, in terms of its high rates of relapse and resistance despite well-established protocols. It is also complicated by the well-known latency in its complete response to current antidepressant treatments. In this context, the search for new strategies regarding antidepressant treatment is mandatory. Revising the use of \u201cold\u201d pharmacotherapies by considering their specific features may help to perfecting the treatment of depression, both in its standalone psychiatric manifestation and in the framework of other clinical conditions. Using a nominal group technique approach, the results of a consensus of expert physicians regarding the possible use of trazodone as a valuable strategy for addressing the \u201creal world\u201d unmet needs of depression treatment in different fields (psychiatry, primary care, neurology and geriatrics) is herein provided. This idea is based on the unique characteristics of this drug which delivers a more rapid antidepressant action as compared to other selective serotonin reuptake inhibitors. It also has pharmacodynamic malleability (i.e., the possibility of exerting different effects on depressive symptoms at different dosages) and pharmacokinetic tolerability (i.e., the possibility of being used as an add-on to other antidepressants with scarce interaction and achieving complimentary effects) when used in the milieu of other drugs in treating comorbid depressive symptoms. Moreover, the large number of formulations available permits finite dosage adjustments, and the use of trazodone for specific pathologies, such as dysphagia. Therefore, although additional studies exploring the real-world conditions of antidepressant treatment are warranted, experts agree on the idea that depressive disorder, in both its standalone and its comorbid manifestations, may surely take advantage of the particular characteristics of trazodone, thus attempting to reach the greatest effectiveness in different contexts.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1207621","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:35:06Z","timestamp":1692246906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone"],"prefix":"10.3389","volume":"14","author":[{"given":"Umberto","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Tomasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Neviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Taddeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"ref1","year":""},{"key":"ref2","year":""},{"key":"ref3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/0019-5359.16261","article-title":"Diagnosis of depression in general practice","volume":"59","author":"Sengupta","year":"2005","journal-title":"Indian J Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00406-013-0448-6","article-title":"Depressive syndromes in neurological disorders","volume":"263","author":"Hellmann-Regen","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Mahli","year":"2018","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e017173","DOI":"10.1136\/BMJOPEN-2017-017173","article-title":"Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis","volume":"7","author":"Wang","year":"2017","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/APPI.AJP.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/070674371005500303","article-title":"The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review","volume":"55","author":"Sinyor","year":"2010","journal-title":"Can J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.4088\/JCP.V67N0912","article-title":"Realistic expectations and a disease management model for depressed patients with persistent symptoms","volume":"67","author":"Keitner","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/WPS.20771","article-title":"The clinical characterization of the adult patient with depression aimed at personalization of management","volume":"19","author":"Maj","year":"2020","journal-title":"World Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the world health surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/S2045796011000345","article-title":"Treating co-morbid chronic medical conditions and anxiety\/depression","volume":"20","author":"Cimpean","year":"2011","journal-title":"Epidemiol Psychiatr Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5498\/wjp.v5.i4.366","article-title":"Treating comorbid anxiety and depression: psychosocial and pharmacological approaches","volume":"5","author":"Coplan","year":"2015","journal-title":"World J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/00002826-198901001-00002","article-title":"Trazodone: from the mental pain to the \u201cdys-stress\u201d hypothesis of depression","volume":"12","author":"Silvestrini","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/s1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"ref19","first-page":"20","article-title":"Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study","volume":"6","author":"Sheehan","year":"2009","journal-title":"Psychiatry"},{"key":"ref20","first-page":"1181","article-title":"Long-term treatment with trazodone once-a-day (TzOAD) in patients with MDD: an observational, prospective study","author":"Shrashimirova","year":"2023"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1708\/3202.31796","article-title":"Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice","volume":"54","author":"Cuomo","year":"2019","journal-title":"Riv Psichiatr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2174\/1570159X20666220310122849","article-title":"Differential response to three antidepressants in patients with major depressive episode who suffered COVID-19-related trauma","volume":"20","author":"De Filippis","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/BRAINSCI13010086\/S1","article-title":"TED\u2014trazodone efficacy in depression: a naturalistic study on the efficacy of trazodone in an extended-release formulation compared to SSRIs in patients with a depressive episode\u2014preliminary report","volume":"13","author":"Siwek","year":"2023","journal-title":"Brain Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000492079","article-title":"Once-a-day trazodone in the treatment of depression in routine clinical practice","volume":"102","author":"\u010ce\u0161kov\u00e1","year":"2018","journal-title":"Pharmacology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/S11096-016-0257-X\/FIGURES\/2","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"ref26","first-page":"7","article-title":"Depression: the case for a monoamine deficiency","volume":"61","author":"Delgado","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/J.EURONEURO.2017.10.032","article-title":"Can we increase speed and efficacy of antidepressant treatments? Part I: general aspects and monoamine-based strategies","volume":"28","author":"Artigas","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.4088\/jcp.v69n0610","article-title":"Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder","volume":"69","author":"Machado-Vieira","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/jama.292.3.338","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Jick","year":"2004","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1176\/appi.ajp.163.1.41","article-title":"Suicide risk during antidepressant treatment","volume":"163","author":"Simon","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s11136-020-02512-7","article-title":"Global mapping of interventions to improve quality of life of patients with depression during 1990\u20132018","volume":"29","author":"Tran","year":"2020","journal-title":"Qual Life Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/ARCHPSYC.63.11.1217","article-title":"Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis","volume":"63","author":"Taylor","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"22cr03430","DOI":"10.4088\/PCC.15r01926","article-title":"Functional recovery in major depressive disorder: focus on early optimized treatment","volume":"18","author":"Habert","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/APPI.AJP.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00441-018-2978-8","article-title":"Monoaminergic system and depression","volume":"377","author":"Perez-Caballero","year":"2019","journal-title":"Cell Tissue Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1017\/S1092852921000304","article-title":"Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action","volume":"26","author":"Albert","year":"2021","journal-title":"CNS Spectr"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e0222855","DOI":"10.1371\/journal.pone.0222855","article-title":"Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and \u03b11-adrenoceptor antagonism","volume":"14","author":"Montalbano","year":"2019","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1017\/S1092852914000169","article-title":"Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/YIC.0000000000000304","article-title":"A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder","volume":"35","author":"Fagiolini","year":"2020","journal-title":"Int Clin Psychopharmacol"},{"key":"ref40","first-page":"294","article-title":"Fluoxetine versus trazodone: efficacy and activating-sedating effects","volume":"52","author":"Beasley","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00004714-199406000-00004","article-title":"Comparison of bupropion and trazodone for the treatment of major depression","volume":"14","author":"Weisler","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000368559","article-title":"Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial","volume":"94","author":"Zhang","year":"2014","journal-title":"Pharmacology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.4088\/JCP.10bs06601gry","article-title":"The serotonin-7 receptor as a novel therapeutic target","volume":"71","author":"Stahl","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/npp.2011.13","article-title":"Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy","volume":"36","author":"Mnie-Filali","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2217\/pgs-2017-0116","article-title":"Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety","volume":"18","author":"Saiz-Rodr\u00edguez","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/FTD.0000000000001049","article-title":"Influence of genetic polymorphisms on the pharmacokinetics of trazodone hydrochloride: a scoping review and future perspective","volume":"45","author":"Meulman","year":"2023","journal-title":"Ther Drug Monit"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/13814780309160405","article-title":"Somatic symptoms and depression in general practice in Italy","volume":"9","author":"Passamonti","year":"2003","journal-title":"Eur J Gen Pract"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000085146","article-title":"Increased recognition of depression in primary care. Comparison between primary-care physician and ICD-10 diagnosis of depression","volume":"74","author":"Berardi","year":"2005","journal-title":"Psychother Psychosom"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eurpsy.2016.04.003","article-title":"How to early recognize mood disorders in primary care: a nationwide, population-based, cohort study","volume":"37","author":"Castellini","year":"2016","journal-title":"Eur Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/S41572-020-0200-2","article-title":"Comorbid depression in medical diseases","volume":"6","author":"Gold","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2215-0366(20)30099-7","article-title":"Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications","volume":"7","author":"Schramm","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1192\/bjp.bp.116.188078","article-title":"Undertreatment of people with major depressive disorder in 21 countries","volume":"210","author":"Thornicroft","year":"2017","journal-title":"Br J Psychiatry"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1080\/13607863.2017.1328480","article-title":"Unmet needs in the depressed primary care elderly and their relation to severity of depression: results from the AgeMooDe study","volume":"22","author":"Alltag","year":"2018","journal-title":"Aging Ment Health"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"106752","DOI":"10.1016\/j.ypmed.2021.106752","article-title":"The association between social needs and chronic conditions in a large, urban primary care population","volume":"153","author":"Heller","year":"2021","journal-title":"Prev Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/09540261.2022.2093629","article-title":"Mental health in transgender individuals: a systematic review","volume":"34","author":"Pinna","year":"2022","journal-title":"Int Rev Psychiatry"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1708\/2168.23450","article-title":"Psychopathology, psychosocial factors and obesity","volume":"51","author":"Pinna","year":"2016","journal-title":"Riv Psichiatr"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"848031","DOI":"10.3389\/fpsyt.2022.848031","article-title":"Depression in diabetic patients: what is the link with eating disorders? Results of a study in a representative sample of patients with type 1 diabetes","volume":"13","author":"Pinna","year":"2022","journal-title":"Front Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.euroneuro.2008.10.003","article-title":"Objective: remission of depression in primary care the Oreon study","volume":"19","author":"Ansseau","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2165\/11530230-000000000-00000","article-title":"Defining and measuring functional recovery from depression","volume":"24","author":"Greer","year":"2010","journal-title":"CNS Drugs"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jad.2011.03.046","article-title":"Clinical effectiveness: the importance of psychosocial functioning outcomes","volume":"132","author":"Lam","year":"2011","journal-title":"J Affect Disord"},{"key":"ref62","first-page":"255","volume-title":"The maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2018"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"727687","DOI":"10.3389\/fpsyt.2021.727687","article-title":"Risk of bleeding associated with antidepressants: impact of causality assessment and competition bias on signal detection","volume":"12","author":"Zeiss","year":"2021","journal-title":"Front Psychiatry"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/14728214.2012.660146","article-title":"Emerging drugs for major depressive disorder","volume":"17","author":"Connolly","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00228-012-1319-1","article-title":"A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care","volume":"69","author":"Trifir\u00f2","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.euroneuro.2014.06.003","article-title":"Identification and treatment of antidepressant tachyphylaxis","volume":"11","author":"Targum","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jad.2018.10.357","article-title":"Tachyphylaxis in major depressive disorder: a review of the current state of research","volume":"245","author":"Kinrys","year":"2019","journal-title":"J Affect Disord"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000288880","article-title":"Do antidepressant and antianxiety drugs increase chronicity in affective disorders?","volume":"61","author":"Fava","year":"1994","journal-title":"Psychother Psychosom"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/SCIENCE.1083328","article-title":"Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants","volume":"301","author":"Santarelli","year":"2003","journal-title":"Science"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/J.MEHY.2011.01.020","article-title":"Tardive dysphoria: the role of long term antidepressant use in-inducing chronic depression","volume":"76","author":"El-Mallakh","year":"2011","journal-title":"Med Hypotheses"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.phrs.2018.11.026","article-title":"Understanding antidepressant tachyphylaxis","volume":"141","author":"Sharma","year":"2019","journal-title":"Pharmacol Res"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1176\/AJP.149.4.443","article-title":"Depression and Parkinson\u2019s disease: a review","volume":"149","author":"Cummings","year":"1992","journal-title":"Am J Psychiatry"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/S00702-021-02456-3","article-title":"Parkinson and depression: review and outlook","volume":"129","author":"Laux","year":"2022","journal-title":"J Neural Transm"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/BS.IRN.2017.05.024","article-title":"Depression and anxiety in Parkinson\u2019s disease","volume":"133","author":"Schrag","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/09540261.2017.1322555","article-title":"Depression in multiple sclerosis","volume":"29","author":"Patten","year":"2017","journal-title":"Int Rev Psychiatry"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"01","DOI":"10.14336\/AD.2023.0310-2","article-title":"Post-stroke neuropsychiatric complications: types, pathogenesis, and therapeutic intervention","author":"Zhou","year":"2023","journal-title":"Aging Dis"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1176\/JNP.15.1.74","article-title":"The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson\u2019s disease: a discriminant analytic approach","volume":"15","author":"Leentjens","year":"2003","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/JNNP.51.11.1401","article-title":"Parkinson\u2019s disease and depression: psychometric properties of the Beck depression inventory","volume":"51","author":"Levin","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/MDS.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov Disord"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/J.1468-1331.2003.00612.X","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicentre prospective randomized study","volume":"10","author":"Rektorov\u00e1","year":"2003","journal-title":"Eur J Neurol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/JNNP.53.7.597","article-title":"Cognitive impairments and depression in Parkinson\u2019s disease: a follow up study","volume":"53","author":"Starkstein","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2174\/0929867324666170712165042","article-title":"New-generation, non-SSRI antidepressants: therapeutic drug monitoring and pharmacological interactions. Part 1: SNRIs, SMSs, SARIs","volume":"25","author":"Mandrioli","year":"2018","journal-title":"Curr Med Chem"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/S00702-017-1830-8","article-title":"Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson\u2019s disease","volume":"125","author":"Hamadjida","year":"2018","journal-title":"J Neural Transm"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1590\/S0004-282X2009000300007","article-title":"The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson\u2019 disease","volume":"67","author":"Werneck","year":"2009","journal-title":"Arq Neuropsiquiatr"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2174\/1570159x14666160115130414","article-title":"Inflammation and immune regulation as potential drug targets in antidepressant treatment","volume":"14","author":"Schmidt","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2174\/1570159X14666151208113700","article-title":"Inflammation in depression and the potential for anti-inflammatory treatment","volume":"14","author":"Kohler","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0022-510X(09)70011-5","article-title":"Multiple sclerosis beyond EDSS: depression and fatigue","volume":"277","author":"Ziemssen","year":"2009","journal-title":"J Neurol Sci"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/J.BBI.2005.03.011","article-title":"A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis","volume":"20","author":"Mohr","year":"2006","journal-title":"Brain Behav Immun"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3389\/FIMMU.2021.677879\/BIBTEX","article-title":"Antidepressants on multiple sclerosis: a review of in vitro and in vivo models","volume":"12","author":"Stamoula","year":"2021","journal-title":"Front Immunol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/3175358","article-title":"Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States","volume":"2017","author":"Bhattacharjee","year":"2017","journal-title":"Mult Scler Int"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/JNNP.71.2.258","article-title":"Relation between depression after stroke, antidepressant therapy, and functional recovery","volume":"71","author":"Gainotti","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1161\/01.STR.28.11.2145","article-title":"Relation of lesion location to verbal and nonverbal mood measures in stroke patients","volume":"28","author":"Gainotti","year":"1997","journal-title":"Stroke"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/S10787-020-00777-5","article-title":"The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies","volume":"29","author":"Dionisie","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/J.PHARMTHERA.2017.11.005","article-title":"Post-stroke depression: mechanisms and pharmacological treatment","volume":"184","author":"Villa","year":"2018","journal-title":"Pharmacol Ther"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/ARCHNEUR.1986.00520080011011","article-title":"Antidepressant therapy after stroke. A double-blind trial","volume":"43","author":"Reding","year":"1986","journal-title":"Arch Neurol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0167-4943(96)86939-1","article-title":"Trazodone therapy of the post-stroke depression","volume":"22","author":"Raffaele","year":"1996","journal-title":"Arch Gerontol Geriatr"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1056\/NEJM198203183061104","article-title":"The nature of suffering and the goals of medicine","volume":"306","author":"Cassel","year":"1982","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0006-3223(02)01468-3","article-title":"Comorbidity of late life depression: an opportunity for research on mechanisms and treatment","volume":"52","author":"Alexopoulos","year":"2002","journal-title":"Biol Psychiatry"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0140-6736(05)66665-2","article-title":"Depression in the elderly","volume":"365","author":"Alexopoulos","year":"2005","journal-title":"Lancet"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/J.JAD.2014.10.010","article-title":"Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study","volume":"172","author":"Fried","year":"2015","journal-title":"J Affect Disord"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother Psychosom"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/JCMM.14170","article-title":"Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment","volume":"23","author":"Fang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/S40266-018-0569-8","article-title":"Insomnia in elderly patients: recommendations for pharmacological management","volume":"35","author":"Abad","year":"2018","journal-title":"Drugs Aging"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000074638","article-title":"Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients","volume":"48","author":"Saletu-Zyhlarz","year":"2003","journal-title":"Neuropsychobiology"},{"key":"ref105","first-page":"359","article-title":"An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer","volume-title":"Am J Hosp Palliat Care","author":"Tanimukai","year":"2012"},{"key":"ref106","year":""},{"key":"ref107","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0006-3223(02)01422-1","article-title":"Medical comorbidity and late life depression: what is known and what are the unmet needs?","volume":"52","author":"Charlson","year":"2002","journal-title":"Biol Psychiatry"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/YCO.0B013E32834BB9D4","article-title":"Depression in dementia: epidemiology, mechanisms, and treatment","volume":"24","author":"Enache","year":"2011","journal-title":"Curr Opin Psychiatry"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1037\/0278-6133.14.5.374","article-title":"Pathways linking affective disturbances and physical disorders","volume":"14","author":"Cohen","year":"1995","journal-title":"Health Psychol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"209","DOI":"10.18773\/AUSTPRESCR.2015.071","article-title":"Depression in dementia","volume":"38","author":"Kitching","year":"2015","journal-title":"Aust Prescr"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","article-title":"Depression and risk of developing dementia","volume":"7","author":"Byers","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S2215-0366(14)70281-0","article-title":"Delirium and depression: inter-relationship and clinical overlap in elderly people","volume":"1","author":"O\u2019Sullivan","year":"2014","journal-title":"Lancet Psychiatry"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"e42751","DOI":"10.1371\/JOURNAL.PONE.0042751","article-title":"Dementia increases the risks of acute organ dysfunction, severe sepsis and mortality in hospitalized older patients: a national population-based study","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"118","DOI":"10.12788\/JHM.2693","article-title":"Screening for depression in hospitalized medical patients","volume":"12","author":"IsHak","year":"2017","journal-title":"J Hosp Med"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1192\/BJP.BP.114.150516","article-title":"Physical exercise for late-life major depression","volume":"207","author":"Belvederi Murri","year":"2015","journal-title":"Br J Psychiatry"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2147\/CIA.S117637","article-title":"Effectiveness of person-centered care on people with dementia: a systematic review and meta-analysis","volume":"12","author":"Kim","year":"2017","journal-title":"Clin Interv Aging"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/J.JAGP.2013.12.174","article-title":"Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study","volume":"22","author":"Camargos","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1089\/JPM.2020.0610","article-title":"Low-dose trazodone for delirium in patients with cancer who received specialist palliative care: a Multicenter prospective study","volume":"24","author":"Maeda","year":"2021","journal-title":"J Palliat Med"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0253717620933436","article-title":"Adjuvant trazodone for management of protracted delirium tremens","volume":"42","author":"Kathiresan","year":"2020","journal-title":"Indian J Psychol Med"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"103024","DOI":"10.1016\/J.AJP.2022.103024","article-title":"Pharmacotherapy for elderly patients with delirium in a general ward setting: a retrospective study","volume":"70","author":"Ohsako","year":"2022","journal-title":"Asian J Psychiatr"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/J.AJP.2017.11.028","article-title":"First- and second-line pharmacological treatment for delirium in general hospital setting-retrospective analysis","volume":"32","author":"Wada","year":"2018","journal-title":"Asian J Psychiatr"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3233\/JAD-181145","article-title":"Long-term trazodone use and cognition: a potential therapeutic role for slow-wave sleep enhancers","volume":"67","author":"La","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"ref123","article-title":"GRN frontotemporal dementia","author":"Hsiung","year":"2020"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1708\/2342.25112","article-title":"Trazodone Contramid\u00ae in clinical practice: personalizing antidepressant intervention","volume":"51","author":"Fagiolini","year":"2016","journal-title":"Riv Psichiatr"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/J.EURONEURO.2018.11.386","article-title":"Intramuscular and intravenous trazodone for the treatment of agitation","volume":"29","author":"Crapanzano","year":"2019","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1207621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:35:18Z","timestamp":1692246918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1207621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":125,"alternative-id":["10.3389\/fpsyt.2023.1207621"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1207621","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"article-number":"1207621"}}